These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 26932443)

  • 1. Cancel the denosumab holiday.
    McClung MR
    Osteoporos Int; 2016 May; 27(5):1677-82. PubMed ID: 26932443
    [No Abstract]   [Full Text] [Related]  

  • 2. Denosumab after 8 years.
    Reid IR
    Osteoporos Int; 2015 Dec; 26(12):2759-61. PubMed ID: 26475285
    [No Abstract]   [Full Text] [Related]  

  • 3. [Osteoporosis treatment can be discontinued based on an individual assessment].
    Eiken PA; Abrahamsen B
    Ugeskr Laeger; 2017 Jan; 179(2):. PubMed ID: 28074765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
    Aubry-Rozier B; Gonzalez-Rodriguez E; Stoll D; Lamy O
    Osteoporos Int; 2016 May; 27(5):1923-5. PubMed ID: 26510845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
    Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
    Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Denosumab After Treatment Discontinuation : A Review of the Literature.
    Iranikhah M; Deas C; Murphy P; Freeman MK
    Consult Pharm; 2018 Mar; 33(3):142-151. PubMed ID: 29720299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
    Lamy O; Gonzalez-Rodriguez E; Stoll D; Hans D; Aubry-Rozier B
    J Clin Endocrinol Metab; 2017 Feb; 102(2):354-358. PubMed ID: 27732330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.
    McCarroll K; Fitzpatrick D; Lannon R
    Osteoporos Int; 2024 Oct; 35(10):1869-1870. PubMed ID: 39120626
    [No Abstract]   [Full Text] [Related]  

  • 9. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
    Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
    Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.
    Kumar S; Gild ML; McDonald MM; Kim AS; Clifton-Bligh RJ; Girgis CM
    Osteoporos Int; 2024 Sep; 35(9):1669-1675. PubMed ID: 38839655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects and management of denosumab discontinuation.
    Chapurlat R
    Joint Bone Spine; 2018 Oct; 85(5):515-517. PubMed ID: 29317292
    [No Abstract]   [Full Text] [Related]  

  • 12. Author response to: OSIN-D-24-00849 Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.
    Kumar S; Gild ML; McDonald MM; Kim AS; Clifton-Bligh RJ; Girgis CM
    Osteoporos Int; 2024 Oct; 35(10):1871-1872. PubMed ID: 39120625
    [No Abstract]   [Full Text] [Related]  

  • 13. [Denosumab in clinical practice : beware before, during and after].
    Lamy O; Gonzalez-Rodriguez E; Stoll D; Aubry-Rozier B
    Rev Med Suisse; 2017 Apr; 13(559):863-866. PubMed ID: 28727345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Same-side insufficiency fractures of the tibia and femur after denosumab discontinuation: a case report.
    Koiwai H; Kamimura M; Nakamura Y; Takahashi J; Taguchi A
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):178-181. PubMed ID: 33019908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fracture risk following intermission of osteoporosis therapy.
    Dennison EM; Cooper C; Kanis JA; Bruyère O; Silverman S; McCloskey E; Abrahamsen B; Prieto-Alhambra D; Ferrari S;
    Osteoporos Int; 2019 Sep; 30(9):1733-1743. PubMed ID: 31175404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
    Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
    Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data.
    Zheng J; van Schaick E; Wu LS; Jacqmin P; Perez Ruixo JJ
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):333-47. PubMed ID: 26123919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observations following discontinuation of long-term denosumab therapy.
    McClung MR; Wagman RB; Miller PD; Wang A; Lewiecki EM
    Osteoporos Int; 2017 May; 28(5):1723-1732. PubMed ID: 28144701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates.
    Uebelhart B; Rizzoli R; Ferrari SL
    Osteoporos Int; 2017 Sep; 28(9):2701-2705. PubMed ID: 28540505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical vertebral fractures following denosumab discontinuation.
    Polyzos SA; Terpos E
    Endocrine; 2016 Oct; 54(1):271-272. PubMed ID: 27393301
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.